Merck faces double threat to lose up to half of its revenue, could a small study with DRTS save it?
Merck announced this week that it is creating a separate cancer business, as it braces for the loss of patent protection on Keytruda, the cancer treatment that accounts for nearly half of the company’s revenue. Merck is taking steps to …